Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio

Biogen Signs a Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio

Shots:

  • Samsung Bioepis to receive $100M up front, up to $210M development, regulatory and commercial milestones and will be responsible for the development and supply of both the products. Biogen to get exclusive commercialization rights for two ophthalmology biosimilars, SB11 referencing Lucentis and SB15 referencing Eylea in the US, Canada, Europe, Japan and Australia
  • Additionally, Biogen will get exclusive right to commercialize anti-TNF portfolio including Benepali (etanercept), Flixabi (infliximab) & Imraldi (adalimumab) in exchange for royalties on sales in China and acquires an option for extending its existing commercial agreement with Samsung Bioepis for anti-TNF portfolio in EU
  • The transaction is expected to be closed in Q4’19. Benapali, Flixabi & Imraldi are the biosimilars referencing Enbrel, Remicade & Humira indicated to treat RA, PsA, axSpA and other autoimmune diseases respectively

Click here to­ read full press release/ article | Ref: Biogen | Image: The Pharma Letter